Wockhardt Limited
Momentum (90/100) does the heavy lifting; valuation (9/100) is the drag.
ExpensiveOvervaluedWockhardt Limited earns a Hold from StocksWizard, with a blended score of 45/100. We put fair value near ₹979.85; at ₹1,959.7 that leaves roughly 50% downside, so the stock screens overvalued by 50%. On 150.6x trailing earnings it sits pricier than the Healthcare median of about 37.6x. The price is about 9% below its 52-week high of ₹2,152.9 and 78% above the low of ₹1,100.3. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9. It clears 6 of 12 investability checks, with durability 41, valuation 18 and momentum 90 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹783.88.
1-year price
EOD · 2026-07-3152-week range
-8.97% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold45Piotroski F-score 4/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 4.0%
- Pass: Low debt (D/E < 0.5): 0.42x
- Fail: Positive free cash flow
- Pass: Revenue growth > 10%: 26%
- No data: Earnings growing
- Fail: Net margin ≥ 10%: 6.3%
- Pass: Current ratio > 1.5: 1.66
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 6.4
- Fail: Piotroski ≥ 7: 4/9
Quarterly results
Annual financials
Shareholding
- Promoter51.0%
- Institutions14.8%
- Public & other34.2%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Financially solid — Altman Z 6.4.
Opportunities
- Revenue growing (26% YoY).
Bear case
Weaknesses
- Low return on equity (4.0%).
Threats
- Rich valuation versus sector peers.
- Trades ~50% above our estimated fair value.
About Wockhardt Limited
Wockhardt Limited manufactures and trades pharmaceuticals, medicinal chemicals, botanical products, and chemical products across India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and other markets. The company develops ZAYNICH zidebactam/cefepime, a novel beta-lactam enhancer antibiotic.
Wockhardt Limited — frequently asked questions
Is Wockhardt Limited a buy, hold or sell?
StocksWizard currently rates Wockhardt Limited (WOCKPHARMA) a Hold, based on a blended score of 45/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Wockhardt Limited's fair value?
Our blended DCF and relative-valuation model estimates Wockhardt Limited's fair value at about ₹979.85, versus a current price of ₹1,959.7 — roughly 50% downside. On that basis the stock looks overvalued by 50%.
Is Wockhardt Limited financially healthy?
Wockhardt Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9.
How has Wockhardt Limited's share price performed?
Wockhardt Limited is up 28% over three months, and last traded at ₹1,959.7. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.